News Formal

Johnson & Johnson's stock climbs after company beats earnings estimates and raises profit guidance

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 33 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 97%

Canada News News

Canada Canada Latest News,Canada Canada Headlines

Johnson & Johnson raised its full year EPS guidance and lifted the midpoint of its sales range

Johnson & Johnson’s stock rose 1.5% in premarket trade Tuesday, after the medtech and drug company posted better-than-expected third-quarter earnings and raised its profit guidance.

Sales rose 6.8% to $21.351 billion from $19.996 billion a year ago, also ahead of the $21.036 billion FactSet consensus. The company spun off its consumer health business earlier this year into a separate company called Kenvue KVUE, +0.88%. Kenvue houses the company’ consumer health business which includes a host of household name brands, including Tylenol, Listerine, Band-Aid, Neutrogena and Nicorette.

It expects full-year EPS to range from $10.02 to $10.08, compared with prior guidance of $9.90 to $10.00. The company expects adjusted EPS to range from $10.07 to $10.13, compared with prior guidance of $10.00 to $10.10.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in CA

Canada Canada Latest News, Canada Canada Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Johnson & Johnson Reports Earnings Tuesday. What to ExpectAn update in August after the split leaves investors with fewer questions for Tuesday's results.
Source: MarketWatch - 🏆 3. / 97 Read more »

Johnson & Johnson earnings: What to expectJohnson & Johnson is not expected to produce big surprises in its earnings release due Tuesday
Source: MarketWatch - 🏆 3. / 97 Read more »

Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.  
Source: NBCLA - 🏆 319. / 59 Read more »

Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.  
Source: NBCNewYork - 🏆 270. / 63 Read more »

Earnings: Early Trend Suggests EPS Growth May Have Already Bottomed in Fiscal Q2Market Overview Analysis by Investing.com (Francesco Casarella) covering: S&P 500, iShares Core S&P 500 ETF, SPDR® S&P 500, S&P 500 Futures. Read Investing.com (Francesco Casarella)'s latest article on Investing.com
Source: Investingcom - 🏆 450. / 53 Read more »